Sandoz Expects Imminent US Pegfilgrastim Action
Seven Months Have Passed Since Refiling With FDA
Sandoz chief Richard Saynor remains confident in the firm’s US pegfilgrastim filing, even though it has been with the FDA for more than six months.
Sandoz chief Richard Saynor remains confident in the firm’s US pegfilgrastim filing, even though it has been with the FDA for more than six months.